

## **West Virginia Medicaid Drug Utilization Review Board Minutes May 25, 2022**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

### **Members:**

Christopher Terpening, PharmD, PhD, Chair  
David Gloss, MD, Vice Chair  
Chris Booth, PharmD  
Scott Brown, RPh  
Kate Forman, PharmD  
Phillip Galapon, MD  
Lester Labus, MD  
Michael Lonsinger, PharmD  
K.C. Lovin, PA-C  
Ernest Miller, DO  
C.K. Babcock, PharmD  
Michael Ballow, PharmD

### **Members Absent:**

Mary Nemeth-Pyles, MSN, RN, CS

### **DHHR/BMS Staff:**

Brian Thompson, MS, PharmD, Director of Pharmacy Services  
Priya Shah, PharmD, Drug Utilization Review Coordinator  
Lori Moles, RPh, Staff Pharmacist  
Bill Hopkins, Pharmacy Operations Manager  
Doug Sorvig, Data Analyst  
Gail Goodnight, RPh, Rebate Manager

### **Contract Staff:**

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)  
Kim Broedel-Zaugg, RPh, PhD, Marshall University  
Rob Stanton, PharmD, MBA, Marshall University  
Jon Willis, Marshall University  
Eric Sears, RPh, Gainwell  
Ryan Fell, PharmD, Change Healthcare  
Laureen Biczak, Change Healthcare

#### **I. INTRODUCTIONS**

- a. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:01 pm EDT. The DUR Board and others introduced themselves.

#### **II. ARRPOVAL OF MINUTES FROM February 16, 2022 DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. **OLD BUSINESS**

IV. **NEW BUSINESS**

a. **Speakers**

- i. None

b. **Updates from April 27, 2022 P & T Committee Meeting**

c. **Report – 1<sup>st</sup> Quarter 2022**

1. **Marshall University – attachment D**

d. **Proposed Prior Authorization Criteria:**

- i. **Adbry:** approved as presented  
ii. **Eprontia:** approved as presented  
iii. **Oral and Topical contraceptives:** approved as presented  
iv. **Atypical Antipsychotics:** approved as presented  
v. **Hepatitis:** approved with change; removing requirement for provider attestation that SUD members are stable and actively enrolled in a treatment plan, and instead, include that language as a recommendation on the Patient-Provider agreement checklist.

V. **REPORTS –4th Quarter 2021**

a. **Gainwell Technologies Quarterly Report:** Mr. Sears presented an overview of the 2022 Second Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.

b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the Second Quarter of 2022. Attachment C

VI. **OTHER BUSINESS**

VII. **NEXT MEETING AND ADJOURNMENT**

a. The meeting concluded at 5:29 pm EDT.

b. The next meeting will be September 28, 2022 from 4-6pm on virtual platform.